FDA clears X-spine's Axle fusion system
This article was originally published in Clinica
The Axle interspinous fusion system developed by X-spine has received 510(k) clearance from the US FDA. The system is designed to provide spinal stability, aiding lumbar fusion, and may be used in the treatment of degenerative disc disease, spinal tumours and trauma. The device causes "far less tissue disruption than traditional spinal fixation systems" according to the Miamisburg, Ohio firm, as it can be implanted through a one-inch incision in the patient's back. The Axle system attaches to the spinous process – the rearmost portion of adjacent vertebrae – of the lower or middle spine. This means that it is away from the spinal cord, spinal nerves and large blood vessels, reducing the possibility of complications.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.